We present a phase III randomized double-blind placebo-controlled multi-center trial that will assess the effect of the aromatase inhibitor letrozole as maintenance therapy in patients with FIGO Stage II-IV low and high-grade ovarian cancer of endometrioid or serous histotype. Here, CYP19A1 is linked to ovarian cancer.